Drugs / MSC-AFP
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03449069 | Jul 2018 → Dec 2023 | Crohn disease, anal fistula | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03220243 | Oct 2017 → Sep 2020 | Crohn disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03209700 | Jul 2017 → Dec 2019 | anal fistula, perianal Crohn disease | William A. Faubion, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT03014219 | Jul 2017 → Jul 2019 | anal fistula | William A. Faubion, M.D. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02589119 | Jan 2016 → Sep 2019 | anal fistula | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01915927 | Jul 2013 → Dec 2019 | perianal Crohn disease | William A. Faubion, M.D. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC-AFP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03209700 ↗ |
| Modality | Cell therapy | “autologous mesenchymal stromal cell transfer” NCT01915927 ↗ |